Echinacea compositum in the treatment of respiratory diseases by Popovich, Sergei V.
REVIEW   ARTICLES
Echinacea compositum in the treatment of respiratory diseases
Sergei V. POPOVIcH
Department of Training, Ukrainian Academy of Biologic Medicine, Kiev, Ukraine
Corresponding author: e-mail.  Received March 14, 2016; accepted April 05, 2016
Abstract
Background: Clinical protocols and standards of treatment of respiratory tract diseases include mainly antibacterial, mucolytic and anti-inflammatory 
therapy. This approach is effective at relieving acute symptoms, but there is a “flip side of the coin” – presence of side effects. So, antibiotics cause 
immunosuppression and dysbiosis, nephrotoxicity and hepatotoxicity. Nonsteroidal anti-inflammatory medicines have a negative effect on mucous 
membrane of stomach and kidneys. Mucolytics, beta-2-agonists increase blood pressure, cause heart rhythm disturbances. In case of a more long-term 
use of these medicines these problems become more relevant.  Thus, there is a shortage of pathogenic anti-inflammatory therapy aimed at optimization 
of inflammation. In standards are absent also effective drainage and detoxification medicines and impossibility of their use in comorbidity, age-related 
limitations also complicates the treatment.
conclusions: Echinacea compositum has a complex effect: detoxification, immunomodulatory, anti-inflammatory, etc. Medication is used in treatment 
of inflammatory and purulent processes of soft tissues and mucous membranes; its prescription does not require prior immunological examination. It 
has a favorable safety profile and is recommended for children from 1 year old, is well combined with any medicine, increases nonspecific protection, 
effectiveness of antibiotic therapy and course of treatment, reduction of its duration; enhances antifungal therapy and is used in the schemes of influenza 
prevention in children, the elderly, patients with tendency to allergic reactions.
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Introduction
Proportion of acute and chronic diseases of the upper and 
lower respiratory tract infections among all newly diagnosed 
diseases is 26% [2]. They significantly reduce quality of life of 
patients, are dangerous with high risk of chronicity and deve-
lopment of complications, especially metagrippal [1]. Here is 
presented the review of long-term foreign clinical experience 
of the use of complex bioregulation medication Echinacea 
compositum of German company “Biologishe Haylmittel 
Heel” for diseases of respiratory tract [4, 5, 6].
Clinical protocols and standards of treatment of respira-
tory tract diseases include mainly antibacterial, mucolytic 
and anti-inflammatory therapy. This approach is effective 
at relieving acute symptoms, but there is a “flip side of the 
coin” - presence of side effects. So, antibiotics cause immuno-
suppression and dysbiosis, nephrotoxicity and hepatotoxicity. 
Nonsteroidal anti-inflammatory medicines have a negative 
effect on mucous membrane of stomach and kidneys. Mu-
colytics, beta-2-agonists increase blood pressure, cause heart 
rhythm disturbances. In case of a more long-term use of these 
medicines these problems become more relevant. [3]
More and more often appears resistance of microorganis-
ms to antimicrobial agents, and the growth of population sen-
sitization limits possibilities to prescribe standard medicines 
[3]. Nonsteroidal anti-inflammatory medicines have mainly 
symptomatic effects on inflammatory process by blocking and 
suppressing it. Thus, there is a shortage of pathogenic anti-
inflammatory therapy aimed at optimization of inflammation. 
In standards are absent also effective drainage and detoxifica-
tion medicines and impossibility of their use in comorbidity, 
age-related limitations also complicates the treatment.
Discussion
In connection with it expansion of the use of pathogenetic 
bioregulation approaches and medications is important as it 
can improve both efficiency and profile of therapy safety. One 
of such approaches is bioregulation. It is carried out through 
the use of integrated bioregulation medicine. Earlier in the 
literature was used the term “antihomotoxic medications”. 
Complex bioregulation medications contain ultralow doses 
of active substances, which contribute to the activation of 
drainage and detoxification processes, recovery of self-con-
trol processes in the body (acute inflammation and others.). 
Ultralow doses of complex bioregulation medication are not 
metabolized in the body and do not have pharmacokinetics. 
They do not require additional energy and do not have phar-
macological load on the body [4, 5, 6].
Complex bioregulation medicine has a pronounced deto-
xification, immune-modulating and anti-inflammatory effect 
– Echinacea compositum (injectable solution).  It is used in 
complex treatment of inflammatory and purulent processes 
of soft tissues and mucous membranes, and particularly in 
cases with severe intoxication and frequent recurrences [1, 
2, 3, 9, 12, 14].
In the National Medical University (Kiev, Ukraine) S. A. 
Kramarev, L. A. Palatnaya, B. K. Shamugia [7] developed 
methodical recommendations “Alternative methods of treat-
ment and prevention of influenza and acute viral infections 
in children” where Echinacea compositum is regarded as a 
universal immunomodulator, which can be administered 
without prior immunological examination that essentially 
simplifies the work of family doctor.
In the Institute of Tuberculosis and Pulmonology of 
the National Academy of Medical Sciences of Ukraine V. P. 
Kostromina, L. B. Yaroshchuk [9] conducted an open, ran-
domized research “Efficacy of antihomotoxic medications 
in the treatment of recurrent bronchitis in children infected 
with mycobacterium of tuberculosis”. The efficiency of CBM 
Echinacea compositum, Limfomiozot (drainage medication, 
which improves lymph drainage) and 2 others were studied. 
The control group received standard therapy. The second, in 
addition Limfomiozot and Mucosa compositum. The third, 
only complex bioregulation medications: Limfomiozot, 
Echinacea compositum, Mucosa compositum and Traumeel.
Made conclusions: monotherapy with complex biore-
gulation medications / antihomotoxic medications in their 
effectiveness is not inferior to the standard scheme of therapy 
of recurrent bronchitis; complex bioregulation medications 
(antihomotoxic medications significantly reduce the level of 
endotoxemia) have a significant normalizing effect on the 
structure and function of mucous membranes of the respira-
tory and digestive tracts and state of microflora [9].
In the research of L. M. Senyuta, G. I. Mazuryak, A. L. 
Tsimbalist, S. S. Moldaver [10] “Therapeutic efficacy and 
tolerability of Echinacea compositum preparation, at various 
stages of treatment of severe pneumonia in infants”, conducted 
on the basis of Regional Children Clinical Hospital in Ivano-
Frankivsk city (Ukraine) were involved 46 children between 
the ages of 1 month to 1 year.
To the first group on the background of basic traditio-
nal therapy was prescribed CBP Echinacea compositum. 
Compared with control group (only basic therapy) the first 
group manifested a significant improvement of general state, 
reduction of the duration of intoxication, obstruction, fever, 
respiratory distress, more rapid normalization of blood for-
mula and reduction of the duration of course of antibiotic 
therapy. Finally, have been made conclusions that parenteral 
use of Echinacea compositum in the treatment of acute vi-
ral and bacterial pneumonia enhances the effectiveness of 
antibiotic therapy and normalization of humoral response; 
it can be recommended for infants for pneumonia therapy, 
for prevention – to children from group at high risk of pne-
umonia development [10]. As a result, by the order No. 18 
of January 13th, 2005 of the Ministry of Health of Ukraine, 
complex bioregulation medication Echinacea compositum is 
included in clinical protocol of the treatment of staphylococcal 
pneumonia in children [11].
In methodological recommendations “Principles of 
etiopathogenic therapy of acute pharyngitis”, S. V. Rya-
zantsev and V. I. Kocherovets [12] characterized Echinacea 
compositum as “biological antibiotic” and noted its high 
efficacy against infectious processes of staphylococcal and 
streptococcal etiology.
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Echinacea compositum greatly enhances antifungal thera-
py in composition of complex treatment of mycoses – metho-
dological recommendations “Clinics and treatment of mycotic 
lesions of upper respiratory tract and ear”. At uncomplicated 
course of mycoses (invasive forms) complex bioregulation 
medications may be administered as monotherapy, and at 
presence of comorbidity - simultaneously with standard 
treatment of mycoses of upper respiratory tract and ear [13].
In the National Medical University (Kiev, Ukraine) P. F. 
Dudka, I. I. Saharchuk, R. I. Ilnitsky [14] developed metho-
dological recommendations “Antihomotoxic medications 
in the treatment of chronic obstructive pulmonary disease”. 
In this case Echinacea compositum is recommended as a 
basic complex bioregulation medication in the scheme of 
chronic obstructive pulmonary disease treatment. Besides 
immunomodulatory action focus is made on its strong an-
ti-inflammatory, indirect antimicrobial, detoxification and 
drainage action.
Conclusions
The use of complex bioregulation medications is pathoge-
netically substantiated method of chronic obstructive pulmo-
nary disease treatment. Both in exacerbation and steady state 
of patient, they enhance clinical efficacy of chronic obstructive 
pulmonary disease treatment, reduce the dosage of antibiotics, 
bronchodilators, inhaled corticosteroids and lower incidence 
of their side effects; in case of non-severe exacerbation of 
chronic obstructive pulmonary disease, caused by respiratory 
viruses, it is possible only the use of complex bioregulation 
medications/ antihomotoxic medications.
Echinacea compositum has a complex effect: detoxificati-
on, immunomodulatory, anti-inflammatory, etc. Medication 
is used in treatment of inflammatory and purulent processes 
of soft tissues and mucous membranes; its prescription does 
not require prior immunological examination. It has a favo-
rable safety profile and is recommended for children from 
1 year old, is well combined with any medicine, increases 
nonspecific protection, effectiveness of antibiotic therapy 
and course of treatment, reduction of its duration; enhances 
antifungal therapy and is used in the schemes of influenza 
prevention in children, the elderly, patients with tendency to 
allergic reactions.
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